Dabigatran etexilate offers predictable pharmacokinetics without the need for routine monitoring or frequent dose adjustments compared to traditional anticoagulants.
May enable fixed-dose anticoagulation without monitoring; leaves open randomized outcome confirmation.
Onset of action 36-72 h 1 h 0.5-2 h Elimination half-life 20-60 h 4.5-7 h 12-14 h Duration of action 48-96 h 12 h 24 h Stable, predictable pharmacokinetics No Yes Yes Interactions with diet and alcohol Yes No No Monitoring INR every 1-4 wk Not monitored No routine monitoring required Dose adjustment Frequent Rarely required Rarely required
No takes yet. Share an insight, caveat, or question.
Hankey et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: